<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509831</url>
  </required_header>
  <id_info>
    <org_study_id>KJ-INT-002</org_study_id>
    <nct_id>NCT03509831</nct_id>
  </id_info>
  <brief_title>[KJ-INT-002] BE Study</brief_title>
  <official_title>A Randomized, Open-label, Crossover Clinical Study to Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 After Oral Administration to Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kukje Pharma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kukje Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 after Oral
      Administration to Healthy Adult Male Subjects
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Actual">January 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>One day</time_frame>
    <description>Pharmacokinetic Characteristics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>One day</time_frame>
    <description>Pharmacokinetic Characteristics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC∞</measure>
    <time_frame>One day</time_frame>
    <description>Pharmacokinetic Characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>One day</time_frame>
    <description>Pharmacokinetic Characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>One day</time_frame>
    <description>Pharmacokinetic Characteristics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Gastritis</condition>
  <arm_group>
    <arm_group_label>INT2150-A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>INT2150-B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INT-2150</intervention_name>
    <description>Period: INT-2150
Period: Irsogladine maleate 2 mg+Nizatidine 150 mg</description>
    <arm_group_label>INT2150-A</arm_group_label>
    <arm_group_label>INT2150-B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irsogladine maleate 2 mg+Nizatidine 150 mg</intervention_name>
    <description>Period: Irsogladine maleate 2 mg+Nizatidine 150 mg
Period: INT-2150</description>
    <arm_group_label>INT2150-A</arm_group_label>
    <arm_group_label>INT2150-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male aged between 19 and 45 years of age inclusive, at the time of signing the
             informed consent.

          2. Body weight &gt;= 50 kilogram (kg) and body mass index within the range 18 - 29.0kg/m^2
             (inclusive).

          3. Healthy as determined by a responsible and experienced physician, based on a medical
             evaluation including medical history, physical examination, laboratory tests and
             cardiac monitoring.

          4. Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form

        Exclusion Criteria:

          1. Patients with a history of abnormal digestive organ, kidney, respiratory,
             neuroendocrine, cardiovascular, hemato-oncology, urinary, muscloskeletal, immune, the
             nose and ears, psychiatry, stomach system.

          2. History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator
             contraindicates their participation.

          3. Systolic blood pressure ≥ 150 or ≤ 100 mmHg, Diasolic blood pressure ≥ 95 or ≤ 55
             mmHg.

          4. Gastrointestinal disease or with gastrointestinal surgical history which can affect
             the absorption of the investigational product.

          5. Alanine aminotransferase, alkaline phosphatase &lt;=2x upper limit of normal (ULN) total
             bilirubin &gt; 2.0mg/dl and eGRF &lt;60mL/min/1.73m2

          6. History of regular alcohol consumption within 6 months of the study defined as: An
             average weekly intake of &gt;21 units for males. One unit is equivalent to 10 gram of
             alcohol.

          7. The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 90 days of the biological effect of the investigational product (whichever is
             longer).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Heon Cho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kukje Pharm</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Nizatidine</mesh_term>
    <mesh_term>Irsogladine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

